Photos
News
- Provectus Reaches Milestone with Completion of Patient Accrual in Phase 2 Trial of PH-10 for Psoriasis
- Provectus Initiates Phase 1 Trial of PV-10 for Liver Cancer
- Provectus Completes Treatment of All Patients in Phase 2 Trial of PV-10 for Metastatic Melanoma
- Provectus Pharmaceuticals Will Present at the Maxim Group Growth Conference on September 29, 2009
- Provectus Pharmaceuticals Will Present at the Rodman & Renshaw 11th Annual Healthcare Conference on September 10, 2009
- Maxim Group LLC Issues Research Report on Provectus Pharmaceuticals, Inc.
- View additional releases
Provectus Annual Report
Related Links
Share
Embed This Player!
Copy the code below to embed this player (video, photos, etc.) into your website!
About Provectus Pharmaceuticals, Inc. (www.pvct.com)
Thank you for your interest in Provectus Pharmaceuticals.We are a group of dedicated and entrepreneurial scientists and business people, working together for the past 12 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies.
Provectus is a significant, emerging player in the huge and growing pharmaceutical industry. We believe in our potential to improve health care worldwide, using breakthrough products that are easy to manufacture and license, and economical to use. We appreciate your interest in our company, and welcome your comments and questions.
Social Media